晚期鼻癌患者的化学放射治疗与放射治疗:第三阶段随机的跨组研究 009999
概括
与单独放射治疗相比,化疗放射治疗显著改善了晚期鼻癌患者的无进展生存率 (PFS) 和整体生存率. 这一发现凸显了联合治疗对更好的患者结果的好处.
科学领域:
- 在瘤学瘤学.
- 辐射瘤学 辐射瘤学
- 医学瘤学 医学瘤学
背景情况:
- 鼻癌 (NPC) 是一种罕见的头癌.
- 晚期NPC的治疗通常包括放射治疗.
- 化疗已经被探索为放射治疗的辅助.
研究的目的:
- 为了比较化学放射治疗与单独放射治疗在患有晚期鼻癌的患者的疗效.
- 评估单独使用化疗或放射治疗治疗的患者的无进展生存期 (PFS) 和整体生存期 (OS).
主要方法:
- 一个随机的III期试验,涉及鼻癌患者.
- 参与者按瘤阶段,结节阶段,表现状况和组织学分层.
- 放射治疗是以每日分数的70 Gy进行的. 实验组在放射治疗期间同时接受了西斯普拉丁化疗,随后是放射治疗后的西斯普拉丁和甲化疗.
主要成果:
- 与单独放射治疗相比,化疗放射疗法显著改善了3年PFS率 (69%vs24%) 和OS率 (78%vs47%).
- 化学辐射治疗组中没有达到PFS的中位数,而放射治疗组的PFS为15个月.
- 化疗放射治疗组的中位生存时间未达到,而放射治疗组的中位生存时间为34个月.
结论:
- 化学辐射疗法是一种优越的治疗方式,与单独的放射疗法相比,用于晚期鼻癌.
- 化学疗法加上放射治疗显著提高了无进展和整体存活率.
- 这些发现支持使用化学辐射疗法作为高级NPC的标准护理.
更多相关视频
06:11Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma
Published on: April 20, 2018
9.8K
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.5K
相关概念视频
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
243
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
243
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
199
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
199
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
332
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
332
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
315
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
315
